Article Text

Download PDFPDF
An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema
  1. D V Do1,
  2. Q D Nguyen1,
  3. S M Shah1,
  4. D J Browning2,
  5. J A Haller1,
  6. K Chu3,
  7. K Yang3,
  8. J M Cedarbaum3,4,
  9. R L Vitti3,
  10. A Ingerman3,
  11. P A Campochiaro1
  1. 1
    The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2
    Charlotte Eye Ear Nose & Throat Associates, P.A., Charlotte, North Carolina, USA
  3. 3
    Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
  4. 4
    Elan Pharmaceuticals, Inc., South San Francisco, California, USA
  1. Dr P A Campochiaro, The Wilmer Eye Institute, 600 North Wolfe Street, Maumenee #719, Baltimore, MD 21287, USA; pcampo{at}


Aim: The aim of the study was to assess the safety and bioactivity of a single intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye in subjects with diabetic macular oedema (DMO).

Methods: Five subjects with DMO, foveal thickness ⩾250 μm measured by optical coherence tomography (OCT), and best-corrected visual acuity (BCVA) between 20/40 and 20/320, were enrolled. Each participant received a single intravitreal injection of 4.0 mg of VEGF Trap-Eye followed by a 6-week observation period. Outcome measures included safety and biological activity, including changes in BCVA and excess retinal thickness assessed by OCT.

Results: Injections of VEGF Trap-Eye were well tolerated with no ocular toxicity. One patient had an unrelated serious adverse event: hospitalisation for cellulitis of the left foot 27 days after injection of VEGF Trap-Eye. Median baseline BCVA was 36 ETDRS letters read at 4 m (not ETDRS visual acuity score; Snellen equivalent: 20/50) and median baseline excess central 1 mm foveal thickness (FTH) was 108 μm. At 4 weeks after injection, the median excess FTH was 59 μm and the median improvement in BCVA was nine letters. At 6 weeks after injection, four of the five patients showed improvement in excess FTH (median 74 μm; 31% reduction from baseline, p = 0.0625) and four of the five showed improvement in BCVA (median improvement of three letters).

Conclusions: A single intravitreal injection of 4.0 mg of VEGF Trap-Eye was well tolerated and preliminary evidence of bioactivity was detected. These findings support additional studies investigating multiple injections of VEGF Trap-Eye in patients with DMO.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This study was funded by Regeneron Pharmaceuticals, Inc.

  • Competing interests: D Do, Q Nguyen, S Shah, D Browning and J Haller have no conflicts of interest. P Campochiaro serves on a data and safety monitoring committee for a clinical trial for NVAMD sponsored by Regeneron. K Chu, K Yang, R Vitti and A Ingerman are employees of Regeneron. J M Cedarbaum is a former employee of Regeneron.

  • Ethics approval: The study was approved by the Western Institutional Review Board.

  • Patient consent: Obtained.

Linked Articles